Andrographolide prevents human breast cancer-induced osteoclastic bone loss via attenuated RANKL signaling

Breast Cancer Research and Treatment

Volumn 144, Issue 1, 2014, Pages 33-45

  Zhai, Zanjing ^a   Qu, Xinhua ^a   Yan, Wei ^b   Li, Haowei ^a   Liu, Guangwang ^c   Liu, Xuqiang ^a   Tang, Tingting ^a   Qin, An ^a   Dai, Kerong ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b Wendeng Zhenggu Hospital of Shandong Province   (China)

^c XUZHOU CENTRAL HOSPITAL   (China)

Author keywords

Andrographolide; Bone metastasis; Breast cancer; Osteoclast; RANKL

Indexed keywords

ANDROGRAPHOLIDE; CASPASE 3; I KAPPA B ALPHA; I KAPPA B KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; OSTEOCLAST DIFFERENTIATION FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BONE METASTASIS; BREAST CANCER; CANCER PREVENTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY TEST; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG ISOLATION; ENZYME INDUCTION; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; METASTASIS INHIBITION; NONHUMAN; OSTEOCLASTOGENESIS; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS INHIBITION;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; BONE NEOPLASMS; BONE RESORPTION; BREAST NEOPLASMS; CELL DIFFERENTIATION; CELL LINE, TUMOR; DITERPENES; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; OSTEOCLASTS; RANK LIGAND; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84894653188     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-014-2844-7     Document Type: Article

References (88)

1. Coleman R (2001) Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 27:165-176
2. Roodman GD (2004) Mechanisms of bone metastasis. N Engl J Med 350:1655-1664
3. Guise TA (2000) Molecular mechanisms of osteolytic bone metastases. Cancer 88:2892-2898
4. Mundy GR (2002) Metastasis: metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2:584-593
5. Roodman GD, Dougall WC (2008) RANK ligand as a therapeutic target for bone metastases and multiple myeloma. Cancer Treat Rev 34:92-101
6. Bhatia P, Sanders MM, Hansen MF (2005) Expression of receptor activator of nuclear factor-kappaB is inversely correlated with metastatic phenotype in breast carcinoma. Clin Cancer Res 11:162-165
7. De Leenheer E, Mueller GS, Vanderkerken K, Croucher PI (2004) Evidence of a role for RANKL in the development of myeloma bone disease. Curr Opin Pharmacol 4:340-346
8. Farrugia AN, Atkins GJ, To LB, Pan B, Horvath N, Kostakis P, Findlay DM, Bardy P, Zannettino AC (2003) Receptor activator of nuclear factor-κB ligand expression by human myeloma cells mediates osteoclast formation in vitro and correlates with bone destruction in vivo. Cancer Res 63:5438-5445
9. Keller ET, Brown J (2004) Prostate cancer bone metastases promote both osteolytic and osteoblastic activity. J Cell Biochem 91:718-729
10. Boyle WJ, Simonet WS, Lacey DL (2003) Osteoclast differentiation and activation. Nature 423:337-342
11. Feng X (2005) RANKing intracellular signaling in osteoclasts. IUBMB Life 57:389-395
12. Kurata T, Nakagawa K (2012) Efficacy and safety of denosumab for the treatment of bone metastases in patients with advanced cancer. Jpn J Clin Oncol 42:663-669
13. Lipton A, Balakumaran A (2012) Denosumab for the treatment of cancer therapy-induced bone loss and prevention of skeletal-related events in patients with solid tumors. Expert Rev Clin Pharmacol 5:359-371
14. Mackiewicz-Wysocka M, Pankowska M, Wysocki PJ (2012) Progress in the treatment of bone metastases in cancer patients. Expert Opin Invest Drugs 21:785-795
15. Paller CJ, Carducci MA, Philips GK (2012) Management of bone metastases in refractory prostate cancer-role of denosumab. Clin Interv Aging 7:363
16. Hillner BE, Ingle JN, Berenson JR, Janjan NA, Albain KS, Lipton A, Yee G, Biermann JS, Chlebowski RT, Pfister DG (2000) American society of clinical oncology guideline on the role of bisphosphonates in breast cancer. J Clin Oncol 18:1378-1391
17. Ernst E (2004) Andrographis paniculata in the treatment of upper respiratory tract infections: a systematic review of safety and efficacy. Planta Med 70:293-298
18. Melchior J, Palm S, Wikman G (1997) Controlled clinical study of standardized Andrographis paniculata extract in common cold: a pilot trial. Phytomedicine 3:315-318
19. Negi AS, Kumar J, Luqman S, Shanker K, Gupta M, Khanuja S (2008) Recent advances in plant hepatoprotectives: a chemical and biological profile of some important leads. Med Res Rev 28:746-772
20. Puri A, Saxena R, Saxena R, Saxena K, Srivastava V, Tandon J (1993) Immunostimulant agents from Andrographis paniculata. J Nat Prod 56:995-999
21. Roxas M, Jurenka J (2007) Colds and influenza: a review of diagnosis and conventional, botanical, and nutritional considerations. Altern Med Rev 12:25-48
22. Thamlikitkul V, Dechatiwongse T, Theerapong S, Chantrakul C, Boonroj P, Punkrut W, Ekpalakorn W, Boontaeng N, Taechaiya S, Petcharoen S (1991) Efficacy of Andrographis paniculata, Nees for pharyngotonsillitis in adults. J Med Assoc Thai 74:437
23. Zhi-ling G, Hua-yue Z, Xin-hua Z (1995) An experimental study of the mechanism of andrographis paniculata nees (APN) in alleviating the Ca(2+)-overloading in the process of myocardial ischemie reperfusion. J Tongji Med Univ 15:205-208
24. Rajagopal S, Kumar RA, Deevi DS, Satyanarayana C, Rajagopalan R (2003) Andrographolide, a potential cancer therapeutic agent isolated from Andrographis paniculata. J Exp Ther Oncol 3:147-158
25. Wang L-J, Zhou X, Wang W, Tang F, Qi C-L, Yang X, Wu S, Lin Y-Q, Wang J-T, Geng J-G (2011) Andrographolide inhibits oral squamous cell carcinogenesis through NF-κB inactivation. J Dent Res 90:1246-1252
26. Chen H-W, Lin A-H, Chu H-C, Li C-C, Tsai C-W, Chao C-Y, Wang C-J, Lii C-K, Liu K-L (2011) Inhibition of TNF-α-induced inflammation by andrographolide via down-regulation of the PI3K/Akt signaling pathway. J Nat Prod 74:2408-2413
27. Chiou WF, Lin JJ, Chen CF (1998) Andrographolide suppresses the expression of inducible nitric oxide synthase in macrophage and restores the vasoconstriction in rat aorta treated with lipopolysaccharide. Br J Pharmacol 125:327-334
28. Shen YC, Chen CF, Chiou WF (2002) Andrographolide prevents oxygen radical production by human neutrophils: possible mechanism (s) involved in its anti-inflammatory effect. Br J Pharmacol 135:399-406
29. Handa S, Sharma A (1990) Hepatoprotective activity of andrographolide against galactosamine and paracetamol intoxication in rats. Indian J Med Res 92:284
30. Trivedi NP, Rawal UM, Patel BP (2009) Potency of andrographolide as an antitumor compound in BHC-induced liver damage. Integr Cancer Ther 8:177-189
31. Jiang X, Yu P, Jiang J, Zhang Z, Wang Z, Yang Z, Tian Z, Wright SC, Larrick JW, Wang Y (2009) Synthesis and evaluation of antibacterial activities of andrographolide analogues. Eur J Med Chem 44:2936-2943
32. Miller FR, Santner SJ, Tait L, Dawson PJ (2000) MCF10DCIS. com xenograft model of human comedo ductal carcinoma in situ. J Natl Cancer Inst 92:1185-1186
33. Nangia-Makker P, Raz T, Tait L, Shekhar MP, Li H, Balan V, Makker H, Fridman R, Maddipati K, Raz A (2013) Ocimum gratissimum retards breast cancer growth and progression and is a natural inhibitor of matrix metalloproteases. Cancer Biol Ther 14:1
34. Nangia-Makker P, Tait L, Shekhar MP, Palomino E, Hogan V, Piechocki MP, Funasaka T, Raz A (2007) Inhibition of breast tumor growth and angiogenesis by a medicinal herb: Ocimum gratissimum. Int J Cancer 121:884-894
35. Tait LR, Pauley RJ, Santner SJ, Heppner GH, Heng HH, Rak JW, Miller FR (2007) Dynamic stromal-epithelial interactions during progression of MCF10DCIS. com xenografts. Int J Cancer 120:2127-2134
36. Hsu H, Lacey DL, Dunstan CR, Solovyev I, Colombero A, Timms E, Tan H-L, Elliott G, Kelley MJ, Sarosi I (1999) Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci USA 96:3540-3545
37. Qin A, Cheng TS, Lin Z, Cao L, Chim SM, Pavlos NJ, Xu J, Zheng MH, Dai KR (2012) Prevention of wear particle-induced osteolysis by a novel V-ATPase inhibitor saliphenylhalamide through inhibition of osteoclast bone resorption. PLoS One 7:e34132
38. Wang C, Steer JH, Joyce DA, Yip KH, Zheng MH, Xu J (2003) 12-O-tetradecanoylphorbol-13-acetate (TPA) inhibits osteoclastogenesis by suppressing RANKL-induced NF-κB activation. J Bone Miner Res 18:2159-2168
39. Akama KT, Albanese C, Pestell RG, Van Eldik LJ (1998) Amyloid beta-peptide stimulates nitric oxide production in astrocytes through an NF-κB-dependent mechanism. Proc Natl Acad Sci USA 95:5795-5800
40. Steer JH, Kroeger KM, Abraham LJ, Joyce DA (2000) Glucocorticoids suppress tumor necrosis factor-alpha expression by human monocytic THP-1 cells by suppressing transactivation through adjacent NF-kappaB and c-Jun-activating transcription factor-2 binding sites in the promoter. J Biol Chem 275:18432-18440. doi: 10.1074/jbc.M906304199
41. Wedemeyer C, Xu J, Neuerburg C, Landgraeber S, Malyar NM, von Knoch F, Gosheger G, von Knoch M, Löer F, Saxler G (2007) Particle-induced osteolysis in three-dimensional micro-computed tomography. Calcif Tissue Int 81:394-402
42. Chikatsu N, Takeuchi Y, Tamura Y, Fukumoto S, Yano K, Tsuda E, Ogata E, Fujita T (2000) Interactions between cancer and bone marrow cells induce osteoclast differentiation factor expression and osteoclast-like cell formation in vitro. Biochem Biophys Res Commun 267:632-637
43. Franzoso G, Carlson L, Xing L, Poljak L, Shores EW, Brown KD, Leonardi A, Tran T, Boyce BF, Siebenlist U (1997) Requirement for NF-kappaB in osteoclast and B-cell development. Genes Dev 11:3482-3496
44. Soysa N, Alles N (2009) NF-κB functions in osteoclasts. Biochem Biophys Res Commun 378:1-5
45. DiDonato JA, Hayakawa M, Rothwarf DM, Zandi E, Karin M (1997) A cytokine-responsive IκB kinase that activates the transcription factor NF-κB. Nature 388:548-554
46. Monje P, Hernández-Losa J, Lyons RJ, Castellone MD, Gutkind JS (2005) Regulation of the transcriptional activity of c-Fos by ERK A novel role for the prolyl isomerase PIN1. J Biol Chem 280:35081-35084
47. Ang E, Liu Q, Qi M, Liu HG, Yang X, Chen H, Zheng MH, Xu J (2011) Mangiferin attenuates osteoclastogenesis, bone resorption, and RANKL-induced activation of NF-κB and ERK. J Cell Biochem 112:89-97
48. Kim HJ, Lee Y, Chang E-J, Kim H-M, Hong S-P, Lee ZH, Ryu J, Kim H-H (2007) Suppression of osteoclastogenesis by N,N-dimethyl-d-erythro-sphingosine: a sphingosine kinase inhibition-independent action. Mol Pharmacol 72:418-428
49. Ikeda F, Nishimura R, Matsubara T, Tanaka S, Inoue J-I, Reddy SV, Hata K, Yamashita K, Hiraga T, Watanabe T (2004) Critical roles of c-Jun signaling in regulation of NFAT family and RANKL-regulated osteoclast differentiation. J Clin Invest 114:475-484
50. Matsumoto M, Sudo T, Saito T, Osada H, Tsujimoto M (2000) Involvement of p38 mitogen-activated protein kinase signaling pathway in osteoclastogenesis mediated by receptor activator of NF-κB ligand (RANKL). J Biol Chem 275:31155-31161
51. David J-P, Sabapathy K, Hoffmann O, Idarraga MH, Wagner EF (2002) JNK1 modulates osteoclastogenesis through both c-Jun phosphorylation-dependent and-independent mechanisms. J Cell Sci 115:4317-4325
52. Lee J-H, Jin H, Shim H-E, Kim H-N, Ha H, Lee ZH (2010) Epigallocatechin-3-gallate inhibits osteoclastogenesis by down-regulating c-Fos expression and suppressing the nuclear factor-κB signal. Mol Pharmacol 77:17-25
53. Lee S, Woo K, Kim S, Kim H-M, Kwack K, Lee Z, Kim H-H (2002) The phosphatidylinositol 3-kinase, p38, and extracellular signal-regulated kinase pathways are involved in osteoclast differentiation. Bone 30:71-77
54. Karin M, Lin A (2002) NF-κB at the crossroads of life and death. Nat Immunol 3:221-227
55. Kucharczak J, Simmons MJ, Fan Y, Gelinas C (2003) To be, or not to be: NF-kappaB is the answer-role of Rel/NF-kappaB in the regulation of apoptosis. Oncogene 22:8961-8982. doi: 10.1038/sj.onc.1207230
56. Pahl HL (1999) Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene 18:6853
57. Chen C-L, Lin C-F, Wan S-W, Wei L-S, Chen M-C, Yeh T-M, Liu H-S, Anderson R, Lin Y-S (2013) Anti-dengue virus nonstructural protein 1 antibodies cause NO-mediated endothelial cell apoptosis via ceramide-regulated glycogen synthase kinase-3β and NF-κB activation. J Immunol 191:1744-1752
58. Ghosh Sankar KM (2002) Missing pieces in the NF-kappaB puzzle. Cell 109(Suppl):81-96
59. Puszynski K, Bertolusso R, Lipniacki T (2009) Crosstalk between p53 and nuclear factor-κB systems: pro-and anti-apoptotic functions of NF-κB. IET Syst Biol 3:356-367
60. Radhakrishnan SK, Kamalakaran S (2006) Pro-apoptotic role of NF-κB: implications for cancer therapy. Biochim Biophys Acta 1766:53-62
61. Cory S, Adams JM (2002) The Bcl2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer 2:647-656
62. Emoto Y, Manome Y, Meinhardt G, Kisaki H, Kharbanda S, Robertson M, Ghayur T, Wong W, Kamen R, Weichselbaum R (1995) Proteolytic activation of protein kinase C delta by an ICE-like protease in apoptotic cells. EMBO J 14:6148
63. Porter AG, Jänicke RU (1999) Emerging roles of caspase-3 in apoptosis. Cell Death Differ 6:99
64. Xue D, Shaham S, Horvitz HR (1996) The Caenorhabditis elegans cell-death protein CED-3 is a cysteine protease with substrate specificities similar to those of the human CPP32 protease. Genes Dev 10:1073-1083
65. Garcia M, Jemal A, Ward E, Center M, Hao Y, Siegel R, Thun M (2007) Global cancer facts and figures 2007. American Cancer Society, Atlanta
66. Society AC (2007) Breast cancer facts and figures 2007-2008. American Cancer Society, Atlanta
67. Coleman R, Smith P, Rubens R (1998) Clinical course and prognostic factors following bone recurrence from breast cancer. Br J Cancer 77:336
68. Coleman RE (1997) Skeletal complications of malignancy. Cancer 80:1588-1594
69. Costa L, Major PP (2009) Effect of bisphosphonates on pain and quality of life in patients with bone metastases. Nat Clin Pract Oncol 6:163-174
70. Body J (2002) Calcitonin for the long-term prevention and treatment of postmenopausal osteoporosis. Bone 30:75S
71. Haskell SG (2003) Selective estrogen receptor modulators. South Med J 96:469-476
72. Rodan GA, Martin TJ (2000) Therapeutic approaches to bone diseases. Science 289:1508-1514
73. Tremollieres F, Lopes P (2002) Specific estrogen receptor modulators (SERMs). Presse Med 31(28):1323-1328
74. Watts NB (2003) Bisphosphonate treatment of osteoporosis. Clin Geriatr Med 19(2):395-414
75. Wood AJJ, Eastell R (1998) Treatment of postmenopausal osteoporosis. N Engl J Med 338:736-746
76. Mariotti A (2008) Bisphosphonates and osteonecrosis of the jaws. J Dent Educ 72:919-929
77. Gevorgyan A, Enepekides DJ (2008) Bisphosphonate-induced necrosis of the jaws: a reconstructive nightmare. Curr Opin Otolaryngol Head Neck Surg 16:325-330
78. Khosla S (2001) Minireview: the OPG/RANKL/RANK system. Endocrinology 142:5050-5055
79. Canon J, Bryant R, Roudier M, Osgood T, Jones J, Miller R, Coxon A, Radinsky R, Dougall WC (2010) Inhibition of RANKL increases the anti-tumor effect of the EGFR inhibitor panitumumab in a murine model of bone metastasis. Bone 46:1613-1619
80. Canon JR, Roudier M, Bryant R, Morony S, Stolina M, Kostenuik PJ, Dougall WC (2008) Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis. Clin Exp Metastasis 25:119-129
81. Morony S, Capparelli C, Sarosi I, Lacey DL, Dunstan CR, Kostenuik PJ (2001) Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis. Cancer Res 61:4432-4436
82. Teitelbaum SL, Ross FP (2003) Genetic regulation of osteoclast development and function. Nat Rev Genet 4:638-649
83. Iotsova V, Caamaño J, Loy J, Yang Y, Lewin A, Bravo R (1997) Osteopetrosis in mice lacking NF-κB1 and NF-κB2. Nat Med 3:1285-1289
84. Xing L, Bushnell TP, Carlson L, Tai Z, Tondravi M, Siebenlist U, Young F, Boyce BF (2002) NF-kappaB p50 and p52 expression is not required for RANK-expressing osteoclast progenitor formation but is essential for RANK- and cytokine-mediated osteoclastogenesis. J Bone Miner Res 17:1200-1210. doi: 10.1359/jbmr.2002.17.7.1200
85. Ruocco MG, Karin M (2007) Control of osteoclast activity and bone loss by IKK subunits: new targets for therapy. Adv Exp Med Biol 602:125-134
86. Ruocco MG, Maeda S, Park JM, Lawrence T, Hsu L-C, Cao Y, Schett G, Wagner EF, Karin M (2005) IκB kinase (IKK) β, but not IKKα, is a critical mediator of osteoclast survival and is required for inflammation-induced bone loss. J Exp Med 201:1677-1687
87. Lee ZH, Kim H-H (2003) Signal transduction by receptor activator of nuclear factor kappaB in osteoclasts. Biochem Biophys Res Commun 305:211-214
88. Biswas DK, Shi Q, Baily S, Strickland I, Ghosh S, Pardee AB, Iglehart JD (2004) NF-κB activation in human breast cancer specimens and its role in cell proliferation and apoptosis. Proc Natl Acad Sci USA 101:10137-10142